Sherko Kuemmel
Advertisement
Articles by Sherko Kuemmel
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study
ByHeather McArthur, MD, MPH,Peter A. Fasching,Rebecca Dent, MD,Javier Cortés, MD,Lajos Pusztai, MD, DPhil,Sherko Kuemmel,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck, MD, PhD,Masato Takahashi,Seock-Ah Im,Michael Untch, MD, PhD,Marie-Ange Mouret-Reynier,Theodoros Foukakis,Marta Ferreira,Fatima Cardoso,Yu Ding,Cecilia Pinheiro,Jaime Mejia,Joyce A. O’Shaughnessy,Peter Schmid, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications
2
FDA Approves Palbociclib Combo in HR+, HER2+ Metastatic Breast Cancer
3
EU Approves Enfortumab Vedotin/Pembrolizumab in Cisplatin-Ineligible MIBC
4
Offering Hope and Support Towards The Cancer Survivorship Journey
5